{
  "docId": "019de077-0326-7579-845c-ff13347b3147",
  "docSlug": "a6759fd47798a8f3f6e744ad8917865e",
  "documentTitle": "Exscientia | Investor Presentation Deck | 93 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 50,
  "pageCount": 93,
  "prevPage": 49,
  "nextPage": 51,
  "slideType": "why_now",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes a biological pathway diagram and a list of potential cancer indications.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de077-0326-7579-845c-ff13347b3147/50",
  "deckHref": "/decks/019de077-0326-7579-845c-ff13347b3147",
  "deckJsonHref": "/decks/019de077-0326-7579-845c-ff13347b3147.json",
  "deckAnchorHref": "/decks/019de077-0326-7579-845c-ff13347b3147#slide-50",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.1,
        "y": 0.65
      },
      "kind": "image",
      "text": "Cancer indications honeycomb",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63bc70e1-7b73-4a23-948a-76fbf3619bb6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "image",
      "text": "Cell cycle diagram and pathway",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2335fbef-2f98-400d-96f3-95125d630f5f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.5,
        "x": 0.43,
        "y": 0.25
      },
      "kind": "list",
      "text": "Importance of cell cycle inhibition: CDK4/6 inhibitors have demonstrated the potential for cell cycle inhibitors to impact cancer; CDK4/6 inhibitors generated $8.9b in sales in 2022; 65-75% of patients show response, but acquire resistance",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0afef20-0069-4e2d-a181-9b258cef9a92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.5,
        "x": 0.43,
        "y": 0.53
      },
      "kind": "list",
      "text": "Transcription and cell cycle dysregulation are both hallmarks of cancer: Inhibiting both may be more effective in controlling growth; Aberrant CDK7 overexpression is common in multiple indications and associated with poor prognosis; Majority of cancers are 'transcriptionally addicted' with c-Myc overexpression",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd132504-9181-4390-8746-4aa3abe06095",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.43,
        "y": 0.83
      },
      "kind": "paragraph",
      "text": "Potential for first line therapy or for CDK4/6 refractory patients",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "716ceddb-30c4-429c-b509-9cb0e0a68384",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.07,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "ER+: Oestrogen receptor positive. About 80% of all breast cancers are ER+. Source: Xu et al. 2020 Nature; Sava et al. 2020 Cancer and Metastasis Reviews",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9f0731e-d055-4c16-a709-1e3d76de52da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Dual targeting of cell cycle and transcription mechanisms",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6afb1d15-1c68-4228-ad67-6a8112ed480a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "CDK7: Inhibition provides broad oncology opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "003a29b5-f255-4129-9bb8-f5ae7638742c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 76,
      "from": 40,
      "beatId": "5ac1e19c-a020-4b03-85c5-f8d4af660d2d",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Highlighting of Exscientia's achievements and partnerships",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}